Skip to content
Global Lines

Zimbabwe Declines ‘Lopsided’ American Healthcare Assistance Agreement Due to Data Fears

Health funding image
The offered US funding would have supported initiatives for HIV/Aids treatment and prevention, TB, and malarial diseases.

Zimbabwe has rejected a major US healthcare agreement worth $367m (£272m) spanning five years due to Washington's demand for sensitive biological samples.

This move came to light after a government memo dated December was leaked, which showed President Emmerson Mnangagwa deemed the agreement was "skewed".

A government spokesman later clarified that the US was seeking genetic material for scientific study and profit while was unwilling to guarantee the benefits from future medical innovations.

"We will now turn to the difficult and regrettable task of winding down our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.

The US Embassy said the US had furnished over $1.9bn as health assistance to Zimbabwe over the last two decades.

A doctors' association in Zimbabwe has called for further negotiations to find a deal acceptable to all parties so the country's vital HIV treatment initiative can proceed.

Broader Background

This rejection follows a similar case in Kenya, where a high court halted a similar deal with the US following concerns were raised about the safety of Kenyans' health data.

After resuming the presidency recently, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.

The agency had overseen assistance for the American government, but Trump argued its expenditure was "inefficient" and his administration was pursuing government-to-government deals to boost transparency and responsibility.

According to statements, Sixteen African countries have so far signed similar health pacts, representing more than $18.3bn of fresh investment.

Specifics of the Declined Deal

The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".

"It is our view this cooperation might have yielded significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children currently receiving antiretroviral therapy via American-funded initiatives," Tremont added.

However, official spokesman Nick Mangwana argued the proposed deal was "unequal".

"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no equivalent guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that provided information," Mangwana explained.

"In essence, our country would provide the raw materials for medical research with no certainty that the resulting innovations would be available to our citizens if a new disease outbreak arise."

Sovereignty and Global Health

He also noted that the American exit from the global health body and its pursuit of one-on-one deals were upending frameworks previously set up through the global health agency.

Mangwana cited its Pandemic Benefit-Sharing framework created to deal with future pandemics.

"This framework is intended to ensure that when a nation contributes its information, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised solely by those with the capability to develop them."

These objections regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.

"We welcome ongoing dialogue with our US partners on how subsequent collaboration could be designed in a way that respects the sovereignty and dignity of both nations."

Health Experts Response

The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the government's concerns, but recommended that negotiations need to persist since a large portion of the country's Aids initiatives were funded by foreign aid.

"If specific concerns arise, including those relating to data governance or implementation frameworks, these can often be resolved through detailed discussion and mutually agreed protections," it commented.

This impasse emphasises the continuing challenges between receiving vital international aid and safeguarding national sovereignty in an increasingly data-driven world.

By

Robert Holt

Elena Vance is a seasoned international business analyst with over 15 years of experience in global markets and trade policy.

Global Lines

Type to search articles.